Zynex

Zynex Debt

Delisted

The Debt of Zynex (ZYXI) as of Nov 22, 2026 is 59.64 M USD. In the previous year, Debt was 58.26 M USD — a change of 2.38% (higher).

Debt

59.64 MUSD

YoY

2.38%

Last updated:

In 2024, Zynex's total debt was 59.64 M USD, a 2.38% change from the 58.26 M USD total debt recorded in the previous year.

The Zynex Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
400,000.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
200,000.00 USD
Jan 1, 2020
400,000.00 USD
Jan 1, 2021
16.40 M USD
Jan 1, 2022
10.90 M USD
Jan 1, 2023
58.26 M USD
Jan 1, 2024
59.64 M USD
The Zynex Debt history
YEARDebtYoY
59.64 MUSD+2.38%
58.26 MUSD+434.48%
10.90 MUSD-33.54%
16.40 MUSD+4,000.00%
400,000.00USD+100.00%
200,000.00USD—
0.00USD-100.00%
400,000.00USD-86.67%
3.00 MUSD-30.23%
4.30 MUSD-10.42%
4.80 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zynex Stock analysis

What does Zynex do? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.

Debt Details

Understanding Zynex's Debt Structure

Zynex's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Zynex's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Zynex’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Zynex’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Zynex stock

Debt of Zynex is 59.64 M USD in 2024.

Debt of Zynex changed from 58.26 M USD to 59.64 M USD, representing a 2.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Zynex since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Zynex historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zynex

All Key Metrics — Zynex